The group's principal activity is to research, develop, manufacture and market advanced transdermal drug delivery products and technologies and prescription transdermal products. The group's products include first generation transdermal estrogen delivery system marketed as vivelle (R), menorest(R) and femiest (r); second generation transdermal estrogen delivery system marketed as vivelle-dot(R) and estradot (r); transdermal combination estrogen/progestin delivery system marketed under the brand name combipatch (r); and dentipatch (r). The group operates in United States and Ireland.
